Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Guided Therapeutics (GTHP) Payables (2016 - 2025)

Guided Therapeutics' Payables history spans 16 years, with the latest figure at $2.5 million for Q4 2025.

  • On a quarterly basis, Payables rose 12.9% to $2.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.5 million, a 12.9% increase, with the full-year FY2025 number at $2.5 million, up 12.9% from a year prior.
  • Payables hit $2.5 million in Q4 2025 for Guided Therapeutics, down from $2.8 million in the prior quarter.
  • Over the last five years, Payables for GTHP hit a ceiling of $2.8 million in Q3 2025 and a floor of $51770.0 in Q1 2023.
  • Historically, Payables has averaged $2.0 million across 5 years, with a median of $2.2 million in 2022.
  • Biggest five-year swings in Payables: plummeted 97.92% in 2023 and later skyrocketed 3662.8% in 2024.
  • Tracing GTHP's Payables over 5 years: stood at $135000.0 in 2021, then soared by 1561.16% to $2.2 million in 2022, then fell by 8.59% to $2.0 million in 2023, then rose by 8.93% to $2.2 million in 2024, then rose by 12.9% to $2.5 million in 2025.
  • Business Quant data shows Payables for GTHP at $2.5 million in Q4 2025, $2.8 million in Q3 2025, and $2.7 million in Q2 2025.